JP Morgan Chase
STRO icon

JP Morgan Chase’s Sutro Biopharma STRO Stock Holding History

JP Morgan Chase’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-741
Closed -$8.57K – 7878
2025
Q4 		$8.57K Sell
741
-6,875
-90% -$65.2K ﹤0.01% 6707
2025
Q3 		$66.1K Sell
7,616
-9,732
-56% -$82.8K ﹤0.01% 6118
2025
Q2 		$124K Sell
17,348
-12,793
-42% -$105K ﹤0.01% 5509
2025
Q1 		$196K Buy
30,141
+23,736
+371% +$374K ﹤0.01% 5248
2024
Q4 		$118K Buy
6,405
+511
+9% +$15.6K ﹤0.01% 5692
2024
Q3 		$204K Buy
5,894
+70
+1% +$2.74K ﹤0.01% 5400
2024
Q2 		$171K Buy
5,824
+950
+19% +$37.6K ﹤0.01% 5239
2024
Q1 		$275K Sell
4,874
-1,740
-26% -$76.9K ﹤0.01% 5163
2023
Q4 		$284K Sell
6,614
-1,068
-14% -$33.9K ﹤0.01% 5139
2023
Q3 		$267K Buy
7,682
+211
+3% +$9.19K ﹤0.01% 4877
2023
Q2 		$347K Buy
7,471
+304
+4% +$15.1K ﹤0.01% 4719
2023
Q1 		$332K Sell
7,167
-11,611
-62% -$737K ﹤0.01% 4746
2022
Q4 		$1.52M Buy
18,778
+3,220
+21% +$224K ﹤0.01% 3768
2022
Q3 		$864K Sell
15,558
-85
-0.5% -$5.03K ﹤0.01% 4112
2022
Q2 		$815K Sell
15,643
-1,434
-8% -$80.1K ﹤0.01% 4245
2022
Q1 		$1.4M Buy
17,077
+11,461
+204% +$1.09M ﹤0.01% 4033
2021
Q4 		$836K Sell
5,616
-56
-1% -$10K ﹤0.01% 4513
2021
Q3 		$1.07M Sell
5,672
-643
-10% -$122K ﹤0.01% 4257
2021
Q2 		$1.17M Buy
6,315
+406
+7% +$79.5K ﹤0.01% 4185
2021
Q1 		$1.34M Sell
5,909
-751
-11% -$178K ﹤0.01% 4003
2020
Q4 		$1.45M Sell
6,660
-581
-8% -$96.2K ﹤0.01% 3713
2020
Q3 		$745K Sell
7,241
-1,006
-12% -$95K ﹤0.01% 3794
2020
Q2 		$640K Sell
8,247
-1,940
-19% -$186K ﹤0.01% 3743
2020
Q1 		$1.04M Sell
10,187
-155
-1% -$16.3K ﹤0.01% 3377
2019
Q4 		$1.14M Buy
10,342
+488
+5% +$50.3K ﹤0.01% 3758
2019
Q3 		$896K Buy
9,854
+350
+4% +$35.3K ﹤0.01% 3897
2019
Q2 		$1.08M Sell
9,504
-82
-0.9% -$9.04K ﹤0.01% 3818
2019
Q1 		$1.09M Sell
9,586
-359
-4% -$37.3K ﹤0.01% 3750
2018
Q4 		$898K Sell
9,945
-60
-0.6% -$7.24K ﹤0.01% 3813
2018
Q3 		$1.5M Buy
+10,005
New +$1.51M ﹤0.01% 3660

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase's STRO Position: Q1 2026 in Review

JP Morgan Chase sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 741 shares — an estimated $8.57K sold.

JP Morgan Chase first reported a position in STRO in Q3 2018 and held it in 30 quarters. The position peaked at $1.52M in Q4 2022. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • JP Morgan Chase reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 741 Sutro Biopharma shares in Q1 2026, an estimated $8.57K.
  • JP Morgan Chase first reported a position in Sutro Biopharma in Q3 2018 and held it in 30 quarters.
  • JP Morgan Chase's Sutro Biopharma position peaked at $1.52M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.